TRK Fusions are Enriched in Cancers with Uncommon Histologies and the Absence of Canonical Driver Mutations

BACKGROUND: TRK inhibitors achieve marked tumor-agnostic efficacy in TRK fusion-positive cancers and consequently are now an established standard of care. Little is known, however, about the demographics, outcomes, response to alternative standard therapies, or genomic characteristics of TRK fusion-...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Clin Cancer Res
Main Authors: Rosen, Ezra Y., Goldman, Debra A., Hechtman, Jaclyn F., Benayed, Ryma, Schram, Alison M, Cocco, Emiliano, Shifman, Sophie, Gong, Yixiao, Kundra, Ritika, Solomon, James P., Bardelli, Alberto, Scaltriti, Maurizio, Drilon, Alexander, Iasonos, Alexia, Taylor, Barry S., Hyman, David M.
Formato: Artigo
Idioma:Inglês
Publicado em: 2019
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7124988/
https://ncbi.nlm.nih.gov/pubmed/31871300
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-19-3165
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados